Fig. 1 · Structure

Documents & Downloads

SCH 563705

Cat. No. A15234 CAS 473728-58-4

CXCR2/CXCR1 antagonist

SCH 563705 is a potent dual CXCR2(IC50= 1.3 nM)/CXCR1(IC50= 7.3 nM) antagonist.

In Stock

Publications for SCH 563705

1 publication citing this product

  1. Yael Derdikman Ofir, .et al. , Mol Ther Oncol, 2026, Jul 1;34(3):201288 PMID: 42519390

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

SCH563705 was used to probe CXCR1/2-dependent signaling in a human mammary epithelial model. At 100 nM, it suppressed invasion of MCF10A acini stimulated by conditioned medium from cells with extra centrosomes. This functional experiment does not measure receptor-binding affinity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
CXCR2 Ki 1 nM
CXCR1 Ki 3 nM
CXCR2 IC50 1.3 nM
CXCR1 IC50 7.3 nM
Mouse CXCR2 IC50 5.2 nM

Cellular Effect

Cell Line Activity Value Description Reference
CHO IC50 1.3 nM Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA [PMID: 17459706]
CHO IC50 7.3 nM Displacement of [125I]IL8 from human CXCR1 expressed in CHO cells by SPA [PMID: 17459706]
Neutrophil IC50 0.5 nM Inhibition of GROalpha-induced migration of human neutrophils by chemotaxis assay [PMID: 17459706]
Neutrophil IC50 37 nM Inhibition of IL8-induced migration of human neutrophils by chemotaxis assay [PMID: 17459706]

SCH 563705 Research Summary

This section summarizes 2 in vitro studies of SCH 563705 from 2 published references.

SCH 563705 In Vitro Studies

In a Matrigel-modified migration assay, SCH563705 (500 nM) suppressed the enhanced migration of Lnk-deficient CD8+ T cells toward B16-F10 melanoma-derived cues. Migrated cells were assessed after 16 h. WT T cells and CD4+ subsets showed no significant inhibitor effect, indicating a response dependent on cell context. [2]

CXCR1/2 inhibitor perturbation of melanoma-directed T-cell migration

Cell-based study · Tumor-draining lymph-node cells from WT and Lnk-deficient mice; Matrigel-modified Boyden chambers with B16-F10 melanoma cells or control medium. [2]

SCH563705 suppressed the enhanced CD8+ T-cell migration of Lnk-deficient cells. The reported inhibitor effect was not significant in WT T cells or CD4+ subsets. This ex vivo assay does not establish drug effects on tumor growth.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Number of CD3+CD8+ cells recovered in the lower chamberDirectional migration response Enhanced Lnk−/− CD8+ migration toward melanoma-derived cues was abrogated by inhibitor pretreatment.[2]
WT T-cell and CD4+ subset migration under inhibitor treatmentReported statistical comparison No significant inhibitor effect on WT T cells or CD4+ subsets of either genotype.[2]

Literature-Reported Treatment Conditions

Treatment concentration
500 nM
Exposure duration
16 h coculture following pretreatment; pretreatment interval not specified in retrieved main text.
Method
Tumor-draining lymph-node cells pretreated before seeding into Matrigel-modified inserts.
Reported limits
Vehicle, pretreatment interval and migration-assay replicate number are not specified in the retrieved main-text method/caption. Supplementary gating/reagent details were not retrieved.
Methods and source locations

Compound reported in the paper: SCH563705

Results apply to the named paper material in this ex vivo model; no lot equivalence is established.

Figure 4D–G (especially F); Results: Lnk deficiency enhances CD8+ T cell migration through the IL-8-CXCR1/2 axis; Methods sec4.9.1 and sec4.11

Number of CD3+CD8+ cells recovered in the lower chamber: Flow cytometry after 16 h; mean ± SEM; two-way ANOVA with multiple comparisons. Exact group means were not transcribed from the graph. — Figure 4F and caption; corresponding Results paragraph

WT T-cell and CD4+ subset migration under inhibitor treatment: Same migration design; these are limiting comparisons within one study, not independent studies. — Figure 4E–G; corresponding Results paragraph

Inhibition of conditioned-medium-driven mammary epithelial invasion

Cell-based study · Human MCF10A recipient acini in 3D Matrigel/collagen-I cultures, exposed to conditioned medium from MCF10A.PLK4 donors with or without induced extra centrosomes. [1]

SCH563705 reduced the paracrine invasive phenotype induced by conditioned medium from cells with extra centrosomes. Reparixin was a separate comparator, not a combination treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Percentage of invasive 3D acinar structuresDirectional inhibition SCH563705 abolished the conditioned-medium-driven paracrine invasion reported by the authors.[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 nM
Exposure duration
3D cultures scored after 4 days; no separate drug-renewal schedule specified in the retrieved assay description.
Method
CXCR1/2 inhibitor applied to recipient 3D cultures receiving conditioned medium.
Co-treatment
Conditioned medium is the experimental stimulus. Reparixin (100 nM) was tested separately.
Reported limits
Drug vehicle and salt/stereochemical composition are not specified in the retrieved assay description.
Methods and source locations

Compound reported in the paper: SCH563705; Compound label in the paper: MedChem Express HY-10011

Nominal compound-level functional evidence in a human epithelial 3D culture model.

Figure 4A and caption; Results: Secreted IL-8 Is Crucial for Paracrine Invasion through Her2 Activation; STAR Methods Cell Culture and drug concentrations; Key Resources Table SCH563705 row

Percentage of invasive 3D acinar structures: 150–200 acini scored per condition per experiment; mean ± SD from three independent experiments. No exact percentages inferred from plotted bars. — Figure 4A and caption; Results CXCR1/2 inhibitor paragraph; STAR Methods Cell Culture

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 473728-58-4
Applications CXCR2/CXCR1 antagonist
Formula C23H27N3O5
Molecular Weight 425.48
SMILES
CCC(C1=CC(=CO1)C(C)C)NC2=C(C(=O)C2=O)NC3=CC=CC(=C3O)C(=O)N(C)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

SCH 563705 Research References

  1. [1] Teresa Arnandis, Pedro Monteiro, Sophie D Adams, et al. Oxidative Stress in Cells with Extra Centrosomes Drives Non-Cell-Autonomous Invasion Developmental Cell (2018). PMID: 30458137 DOI: 10.1016/j.devcel.2018.10.026 Source material
  2. [2] Yael Derdikman Ofir, Miran Aswad, Michal Hayun, et al. Lnk Governs chemokine-directed trafficking of CD8+ T cells in melanoma Molecular Therapy Oncology (2026). PMID: 42519390 DOI: 10.1016/j.omton.2026.201288 Source material

Publications

1 publication citing this product

  1. Yael Derdikman Ofir, .et al. , Mol Ther Oncol, 2026, Jul 1;34(3):201288 PMID: 42519390

Added to your cart

View Cart Checkout
Loading...